MIRA PHARMACEUTICALS, INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.746 USD | -1.83% |
|
-7.66% | -28.95% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 11.23M |
|---|---|---|---|---|---|
| Net income 2024 * | -7M | Net income 2025 * | -6M | EV / Sales 2024 * | - |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 70.95% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -1.83% | ||
| 1 week | -7.66% | ||
| Current month | -12.22% | ||
| 1 month | -25.41% | ||
| 3 months | -36.24% | ||
| 6 months | -49.59% | ||
| Current year | -28.95% |
1 week
0.72
0.86
1 month
0.721.02
Current year
0.721.84
1 year
0.727.98
3 years
0.727.98
5 years
0.727.98
10 years
0.727.98
| Managers | Title | Age | Since |
|---|---|---|---|
Erez Aminov
CEO | Chief Executive Officer | 46 | 23-03-31 |
Michelle Yanez
DFI | Director of Finance/CFO | 52 | 22-04-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| - | - | ||
Michael Jerman
BRD | Director/Board Member | 40 | Nov. 13 |
Erez Aminov
CEO | Chief Executive Officer | 46 | 23-03-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-09 | 0.746 | -1.83% | 8 606 |
| 24-05-08 | 0.7599 | -0.01% | 9,117 |
| 24-05-07 | 0.76 | +1.33% | 16,107 |
| 24-05-06 | 0.75 | +2.32% | 71,133 |
| 24-05-03 | 0.733 | -9.27% | 324,524 |
Delayed Quote Nasdaq, May 09, 2024 at 09:55 am EDT
More quotes
MIRA Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical development company. The Company has two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. It holds exclusive license rights in the United States, Canada and Mexico for Ketamir-2, a patent pending oral ketamine analog under pre-clinical investigation to potentially deliver ultra-rapid antidepressant effects, providing hope for individuals battling treatment-resistant depression (TRD), major depressive disorder with suicidal ideation (MDSI) and potentially post-traumatic stress disorder (PTSD). Its oral pharmaceutical marijuana molecule, MIRA-55, is being studied for its potential to alleviate neuropathic pain, as well as anxiety and cognitive decline, symptoms commonly associated with early-stage dementia.
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -28.95% | 11.23M | |
| +25.04% | 46.71B | |
| +48.83% | 41.8B | |
| -1.11% | 41.52B | |
| -3.42% | 29.55B | |
| +10.63% | 25.78B | |
| -20.94% | 19.26B | |
| +1.66% | 12.14B | |
| -3.59% | 12.08B | |
| +27.26% | 11.98B |
- Stock Market
- Equities
- MIRA Stock